Reach Us +44-1904-929220
The Cytoskeleton as Biomarker: Angiosarcoma- Cytoskeleton | OMICS International
Journal of Molecular Biomarkers & Diagnosis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

The Cytoskeleton as Biomarker: Angiosarcoma- Cytoskeleton

Shifalika Tangutoori*

Postdoctoral Research Associate in Nanomedicine, Northeastern University, USA

Visiting Scientist, Dept of Radiation Oncology, Dana Farber Cancer Institute, USA

*Corresponding Author:
Shifalika Tangutoori
Postdoctoral Research Associate in Nanomedicine
Northeastern University, USA
Tel: 617-373-8220
Fax: 617-373-2823
E-mail: [email protected]; [email protected]; [email protected]

Received Date: September 26, 2014; Accepted Date: September 29, 2014; Published Date: October 02, 2014

Citation: Tangutoori S. (2014) The Cytoskeleton as Biomarker: Angiosarcoma- Cytoskeleton. J Mol Biomark Diagn 5:i101. doi:10.4172/2155-9929.1000I101

Copyright: © 2014 Tangutoori S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Journal of Molecular Biomarkers & Diagnosis



Short Description

The cytoskeleton as biomarker: The cytoskeleton often serves as a reliable biomarker of stress and antimitotic effects induced by various classes of anticancer drugs on tumor cells. The organization of cellular cytoskeleton of an angiosarcoma cell, MS1-VEGF, is depicted using FITC-β-tubulin antibody as the immunofluorescence indicator. The cytoskeletal changes can be probed before and after cancer therapy to detect the extent of vascular disruption and vascular shutdown. Green represents the cytoskeleton, blue represent the nucleus of the angiosarcoma cell.


Image acquired in Bouve College of health Sciences, Department of Pharmaceutical Sciences, Campbell Lab (31 MU); Northeastern University, Boston-MA.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12385
  • [From(publication date):
    October-2014 - Dec 13, 2019]
  • Breakdown by view type
  • HTML page views : 8582
  • PDF downloads : 3803